BNP/CALL/NOVO-NORDISK B/850/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 10:21:13 2024-07-04 EDT | ||
| 2.31 EUR | -0.86% |
|
| Current month | -14.96% | ||
| 1 month | +20.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 2.31 | -0.86% |
| 24-07-03 | 2.33 | -2.10% |
| 24-07-02 | 2.38 | -8.81% |
| 24-07-01 | 2.61 | -4.74% |
| 24-06-28 | 2.74 | +3.01% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 10:21 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC367Q |
| ISIN | DE000PC367Q9 |
| Date issued | 2024-01-30 |
| Strike | 850 kr |
| Maturity | 2024-12-20 (169 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.9 € |
|---|---|
| Lowest since issue | 0.82 € |
| Spread | 0.02 € |
| Spread % | 0.85% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
